Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCG-Refractory Bladder Cancer”

76 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 76 results

Testing effectiveness (Phase 2)Study completedNCT01687244
What this trial is testing

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
FKD Therapies Oy 40
Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Early research (Phase 1)Not Yet RecruitingNCT07725796
What this trial is testing

Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. 30
Early research (Phase 1)WithdrawnNCT03552796
What this trial is testing

SEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaBladder Cancer Stage 0Bladder Cancer Stage I
University of Southern California
Testing effectiveness (Phase 2)Looking for participantsNCT03945162
What this trial is testing

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc. 90
Large-scale testing (Phase 3)Ended earlyNCT01200992
What this trial is testing

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, Carcinoma+2 more
Bioniche Life Sciences Inc. 84
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Testing effectiveness (Phase 2)Ended earlyNCT02901548
What this trial is testing

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Who this might be right for
Carcinoma in Situ of BladderBladder Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Testing effectiveness (Phase 2)Study completedNCT02009332
What this trial is testing

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer (NMIBC)
Aadi Bioscience, Inc. 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06310369
What this trial is testing

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 50
Early research (Phase 1)Looking for participantsNCT05519241
What this trial is testing

A Phase I Intravesical PPM Therapy for NMIBC

Who this might be right for
Non-muscle-invasive Bladder Cancer
VA Office of Research and Development 29
Testing effectiveness (Phase 2)Ended earlyNCT01118351
What this trial is testing

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Who this might be right for
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center 19
Not applicableStudy completedNCT01304173
What this trial is testing

Retrospective Chart Review of Valstar

Who this might be right for
Carcinoma in Situ of Bladder
Endo USA Inc., a Keenova Therapeutics Company 113
Not applicableEnded earlyNCT04142359
What this trial is testing

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Who this might be right for
Pharmacokinetics
Altor BioScience 1
Early research (Phase 1)Active Not RecruitingNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 6
Not applicableEnded earlyNCT01314664
What this trial is testing

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder CancerCIS
Endo USA Inc., a Keenova Therapeutics Company 15
Not applicableLooking for participantsNCT06990061
What this trial is testing

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study

Who this might be right for
Non-Muscle Invasive Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 50
Testing effectiveness (Phase 2)Looking for participantsNCT07747740
What this trial is testing

Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Non-Muscle-Invasive Bladder CancerBCG-Unresponsive Bladder Cancer
Blokhin's Russian Cancer Research Center 228
Not applicableAvailableNCT06443944
What this trial is testing

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Who this might be right for
Non-Muscle Invasive Bladder CancerUrothelial CarcinomaUrologic Cancer+1 more
CG Oncology, Inc.
Next Page